| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Point-Counterpoint Reviews |
1 Genomic Medicine Institute, Lerner Research Institute and 2 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio; 3 Department of Genetics and 4 CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio; Departments of 5 Molecular Genetics, 6 Biochemistry and Molecular Biology, and 7 Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
Requests for reprints: Charis Eng, Cleveland Clinic Genomic Medicine Institute, 9500 Euclid Avenue, NE-50, Cleveland, OH 44195. Phone: 216-444-3440; Fax: 216-636-0655; E-mail: engc{at}ccf.org.
Key Words: genomics microenvironment stroma
Abstract
It was traditionally believed that the tumor was the seed that lay in the passive soil of the microenvironment, with the latter providing "permissive elements" for the tumor to grow and invade. Subsequently, it was recognized that both neoplasia and its microenvironment interacted as equal partners. Recent advances addressing genomic alterations in the tumor microenvironment, relevant to clinical outcome and treatment choices, are summarized. These include microenvironmental genomic alterations not only in different solid tumors, but also, rather surprisingly, in inflammatory bowel disease. These observations promise new biomarkers of prognosis and a new compartment to target therapy. [Cancer Res 2009;69(17):6759–64]
This article has been cited by other articles:
![]() |
G. C. Prendergast Stromal Mutations and Notch/Nodal Signaling in Cancer Cancer Reviews Online Content, January 1, 2009; 2009(10): 19 - 19. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |